These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
416 related articles for article (PubMed ID: 23910650)
1. Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate. Pradat P; Le Pogam MA; Okon JB; Trolliet P; Miailhes P; Brochier C; Maynard M; Bailly F; Zoulim F; Cotte L J Viral Hepat; 2013 Sep; 20(9):650-7. PubMed ID: 23910650 [TBL] [Abstract][Full Text] [Related]
2. Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir. Tan LK; Gilleece Y; Mandalia S; Murungi A; Grover D; Fisher M; Atkins M; Nelson M J Viral Hepat; 2009 Jul; 16(7):471-8. PubMed ID: 19457140 [TBL] [Abstract][Full Text] [Related]
3. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Peters MG; Andersen J; Lynch P; Liu T; Alston-Smith B; Brosgart CL; Jacobson JM; Johnson VA; Pollard RB; Rooney JF; Sherman KE; Swindells S; Polsky B; Hepatology; 2006 Nov; 44(5):1110-6. PubMed ID: 17058225 [TBL] [Abstract][Full Text] [Related]
4. Renal outcomes after up to 8 years of tenofovir exposure in HIV-HBV-coinfected patients. Boyd A; Miailhes P; Lascoux-Combe C; Rougier H; Girard PM; Plaisier E; Lacombe K Antivir Ther; 2017; 22(1):31-42. PubMed ID: 27553871 [TBL] [Abstract][Full Text] [Related]
5. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. Nishijima T; Kawasaki Y; Tanaka N; Mizushima D; Aoki T; Watanabe K; Kinai E; Honda H; Yazaki H; Tanuma J; Tsukada K; Teruya K; Kikuchi Y; Gatanaga H; Oka S AIDS; 2014 Aug; 28(13):1903-10. PubMed ID: 25259702 [TBL] [Abstract][Full Text] [Related]
6. Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir. Trinh S; Le AK; Chang ET; Hoang J; Jeong D; Chung M; Lee MH; Wang U; Henry L; Cheung R; Nguyen MH Clin Gastroenterol Hepatol; 2019 Apr; 17(5):948-956.e1. PubMed ID: 30130625 [TBL] [Abstract][Full Text] [Related]
8. Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia. Childs K; Joshi D; Byrne R; Bruce M; Carey I; Agarwal K; Taylor C AIDS; 2013 Jun; 27(9):1443-8. PubMed ID: 23435302 [TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort. Alvarez-Uria G; Ratcliffe L; Vilar J HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695 [TBL] [Abstract][Full Text] [Related]
11. Increased time exposure to tenofovir is associated with a greater decrease in estimated glomerular filtration rate in HIV patients with kidney function of less than 60 ml/min/1.73 m2. Fafin C; Pugliese P; Durant J; Mondain V; Rahelinirina V; De Salvador F; Ceppi C; Perbost I; Rosenthal E; Roger PM; Cua E; Dellamonica P; Esnault V; Pradier C; Moranne O Nephron Clin Pract; 2012; 120(4):c205-14. PubMed ID: 23037894 [TBL] [Abstract][Full Text] [Related]
12. Tenofovir disoproxil fumarate-associated nephrotoxicity in HIV-infected patients: a prospective controlled study. Woratanarat K; Kanjanabuch T; Suankratay C J Med Assoc Thai; 2013 Apr; 96(4):432-9. PubMed ID: 23691697 [TBL] [Abstract][Full Text] [Related]
13. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. Mauss S; Berger F; Filmann N; Hueppe D; Henke J; Hegener P; Athmann C; Schmutz G; Herrmann E J Hepatol; 2011 Dec; 55(6):1235-40. PubMed ID: 21703180 [TBL] [Abstract][Full Text] [Related]
15. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV. Zoutendijk R; Zaaijer HL; de Vries-Sluijs TE; Reijnders JG; Mulder JW; Kroon FP; Richter C; van der Eijk AA; Sonneveld MJ; Hansen BE; de Man RA; van der Ende ME; Janssen HL J Infect Dis; 2012 Sep; 206(6):974-80. PubMed ID: 22782950 [TBL] [Abstract][Full Text] [Related]
16. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Matthews GV; Avihingsanon A; Lewin SR; Amin J; Rerknimitr R; Petcharapirat P; Marks P; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ Hepatology; 2008 Oct; 48(4):1062-9. PubMed ID: 18697216 [TBL] [Abstract][Full Text] [Related]
17. Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression. Huang AJ; Núñez M J Int Assoc Provid AIDS Care; 2015; 14(4):360-8. PubMed ID: 25999329 [TBL] [Abstract][Full Text] [Related]
18. Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate ≥ 60 ml/min per 1.73 m2. Reynes J; Cournil A; Peyriere H; Psomas C; Guiller E; Chatron M; Cristol JP; Badiou S AIDS; 2013 May; 27(8):1295-302. PubMed ID: 23925378 [TBL] [Abstract][Full Text] [Related]
19. Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. Plaza Z; Aguilera A; Mena A; Vispo E; Sierra-Enguita R; Tomé S; Pedreira J; Rodriguez C; Barreiro P; del Romero J; Soriano V; Poveda E AIDS; 2013 Sep; 27(14):2219-24. PubMed ID: 23669158 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ; J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]